Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.
View Top Employees from Crescendo Biologics LimitedWebsite | http://www.crescendobiologics.com |
Revenue | $9 million |
Funding | $73.3 million |
Employees | 62 (56 on RocketReach) |
Founded | 2009 |
Phone | +44 1223 497140 |
Technologies |
JavaScript,
HTML,
PHP
+18 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Health Care, Therapeutics |
Web Rank | 19 Million |
Keywords | Crescendo Biologics, Crescendo Biologics Limited |
Competitors | Harpoon Therapeutics, LAVA Therapeutics N.V., ModiQuest B.V., Synthetic Biologics, Inc., Teneobio, Inc. |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular Crescendo Biologics Limited employee's phone or email?
The Crescendo Biologics Limited annual revenue was $9 million in 2024.
Julia Tilson is the COO of Crescendo Biologics Limited.
56 people are employed at Crescendo Biologics Limited.
The NAICS codes for Crescendo Biologics Limited are [5417, 541, 54, 541714, 54171].
The SIC codes for Crescendo Biologics Limited are [873, 87].